NCT04744532 - iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Bosutinib (Phase 1 part)

Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.

DRUG

Bosutinib (Phase 2 part)

Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.

Trial Locations (7)

RECRUITING

Hiroshima University, Hiroshima

RECRUITING

Nara Medical University, Kashihara

RECRUITING

Kyoto University, Kyoto

RECRUITING

Kitasato University, Sagamihara

RECRUITING

Tokushima university, Tokushima

RECRUITING

Toho University, Tokyo

RECRUITING

Tottori University, Yonago